1型和2型糖尿病肾病中糖酵解酶与PKM2的特征分析
研究分析非Medalist 1型糖尿病(n=15)、2型糖尿病(n=19)及无糖尿病(n=5)死者肾小球中糖酵解和线粒体酶,并对Medalist血浆行蛋白质组学和代谢组学筛查。发现2型糖尿病CKD-者肾小球PKM1、PKM2、ENO1和MTCO2显著升高,Medalist血浆PKM2与eGFR相关,循环中糖酵解酶升高与肾保护相关。
要点
- 2型糖尿病CKD-者肾小球糖酵解酶和线粒体酶显著高于CKD+者
- Medalist血浆PKM2与eGFR相关(r²=0.077;P=0.0002)
- 循环糖酵解酶升高和毒性代谢物降低可反映肾保护状态
核心结论
- 肾小球中参与细胞内游离葡萄糖及其代谢物代谢的酶升高与1型和2型糖尿病肾功能保护相关。
- 升高的糖酵解酶和降低的毒性葡萄糖代谢物的肾脏特征反映在循环中,支持其作为内源性肾保护因素生物标志物。
研究设计与样本
- 免疫印迹分析非Medalist 1型糖尿病(n=15)、2型糖尿病(n=19)和无糖尿病(n=5)死者肾小球中选定的糖酵解和线粒体酶。
- 对伴或不伴3b期慢性肾脏病(CKD)的Medalist进行血浆蛋白质组学(SOMAscan)(n=180)和代谢组学筛查(n=214),并用ELISA验证显著标志物。
主要发现
- 在2型糖尿病CKD-者肾小球中,糖酵解酶(PKM1、PKM2和ENO1)和线粒体酶(MTCO2)显著高于CKD+者。
- Medalist血浆PKM2与估算肾小球滤过率(eGFR)相关(r²=0.077;P=0.0002)。
- 在CKD保护的Medalist中,循环中几种葡萄糖和线粒体酶上调,同时毒性代谢物相应下调。
- 淀粉样前体蛋白也显著上调,肿瘤坏死因子受体下调,两者均经ELISA确认。
临床怎么用
- 肾小球糖酵解酶升高和毒性葡萄糖代谢物降低的循环特征可能作为糖尿病内源性肾保护因素的生物标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Elevated glycolytic enzymes in renal glomeruli correlated with preservation of renal function in the Medalist Study, individuals with ≥50 years of type 1 diabetes. Specifically, pyruvate kinase M2 (PKM2) activation protected insulin-deficient diabetic mice from hyperglycemia-induced glomerular pathology. This study aims to extend these findings in a separate cohort of individuals with type 1 and type 2 diabetes and discover new circulatory biomarkers for renal protection through proteomics and metabolomics of Medalists' plasma. We hypothesize that increased glycolytic flux and improved mitochondrial biogenesis will halt the progression of diabetic nephropathy. RESEARCH DESIGN AND METHODS: Immunoblots analyzed selected glycolytic and mitochondrial enzymes in postmortem glomeruli of non-Medalists with type 1 diabetes (n = 15), type 2 diabetes (n = 19), and no diabetes (n = 5). Plasma proteomic (SOMAscan) (n = 180) and metabolomic screens (n = 214) of Medalists with and without stage 3b chronic kidney disease (CKD) were conducted and significant markers validated by ELISA. RESULTS: Glycolytic (PKM1, PKM2, and ENO1) and mitochondrial (MTCO2) enzymes were significantly elevated in glomeruli of CKD- versus CKD+ individuals with type 2 diabetes. Medalists' plasma PKM2 correlated with estimated glomerular filtration rate (r 2 = 0.077; P = 0.0002). Several glucose and mitochondrial enzymes in circulation were upregulated with corresponding downregulation of toxic metabolites in CKD-protected Medalists. Amyloid precursor protein was also significantly upregulated, tumor necrosis factor receptors downregulated, and both confirmed by ELISA. CONCLUSIONS: Elevation of enzymes involved in the metabolism of intracellular free glucose and its metabolites in renal glomeruli is connected to preserving kidney function in both type 1 and type 2 diabetes. The renal profile of elevated glycolytic enzymes and reduced toxic glucose metabolites is reflected in the circulation, supporting their use as biomarkers for endogenous renal protective factors in people with diabetes.
引用
- Gordin D, Shah H, Shinjo T, et al. Characterization of Glycolytic Enzymes and Pyruvate Kinase M2 in Type 1 and 2 Diabetic Nephropathy. Diabetes Care. 2019. PMID: 31076418. doi:10.2337/dc18-2585
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。